New surgical approach for women at risk of ovarian cancer

August 24, 2020

A new two-stage surgical approach for cancer prevention is highly acceptable among premenopausal women at high risk of ovarian cancer, according to research led by Queen Mary University of London.

For women at high risk of ovarian cancer, the standard preventive practice is to offer removal of both the fallopian tubes and ovaries, but the surgery induces menopause in women who have not yet reached this stage of life. Early menopause is associated with side effects like increased risk of heart-disease, osteoporosis, neurocognitive decline and sexual-dysfunction. Hence, some women at high risk of ovarian cancer delay surgery until after they reach menopause. During this period they remain at much higher risk of ovarian cancer.

A proposed alternative is a two-step surgical protocol, which delays the induced menopause caused by the removal of the ovaries. In this protocol, the fallopian tubes are removed as an initial step to offer some risk reduction, and ovary removal is delayed until a later stage when women have reached menopause. This procedure provides some ovarian cancer risk reduction while avoiding detrimental consequences of premature surgically-induced menopause.

69 per cent interested in new surgical option

In the multicentre UK study, published in the British Journal of Obstetrics and Gynaecology and funded by the Rosetrees Trust and Barts Charity, researchers examined the acceptability of the proposed alternative two-step surgical protocol. The 638 study participants were all at increased risk of ovarian cancer; 346 had undergone standard risk reducing surgery, and 337 had not.

Among those who had undergone standard preventive surgery, 9.4 per cent of premenopausal and 1.2 per cent of postmenopausal women regretted their decision. Of premenopausal women who had not undergone standard surgery, 69 per cent found it acceptable to participate in a research study offering the proposed new surgical option. 38 per cent of women who had undergone standard surgery would have potentially (in hindsight) opted for the new two-step operation. The new two-step surgical protocol was particularly acceptable to women concerned about the sexual dysfunction side effects of ovary removal.

Patients sought for clinical trial into new surgery protocol

Lead researcher Professor Ranjit Manchanda from Queen Mary University of London and Barts Health NHS Trust said: "Undergoing an operation to prevent ovarian cancer can be a complex decision making process. Although removal of tubes and ovaries prevents ovarian cancer, it can lead to early surgical menopause which has significant detrimental consequences on long-term health. A number of women opt to delay or decline preventive surgery as a result.

"The new two-step operation offers additional options for women (who may have not undergone surgical prevention) to reduce their ovarian cancer risk while avoiding the negative impact of early menopause. Our study shows a large proportion of eligible women wish to consider this. UK women who wish to do so now have the option of joining the PROTECTOR (Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal) study ("

Dr Faiza Gaba from Queen Mary University of London added: "While hormone replacement therapy (HRT) has been shown to mitigate some symptoms, it does not appear to alleviate sexual-dysfunction or increase satisfaction levels following standard preventive surgery involving removal of ovaries. However HRT-use in breast cancer unaffected women undergoing premenopausal removal of their ovaries is essential to reduce the risk of heart disease, osteoporosis and neurocognitive decline. The new two-step surgery offers further options to women considering surgical prevention."

Treatments designed around women's individual needs and choices

Dr Vineeth Rajkumar, Head of Research at Rosetrees Trust said: "Rosetrees Trust is delighted to have supported Professor Manchanda's study, which has paved the way for a clinical trial that could make a difference to thousands of women at risk of ovarian cancer."

Victoria King, Director of Grants at Barts Charity added: "Barts Charity is proud to support the PROTECTOR trial, a trial which could make a huge difference to women with increased risk of ovarian cancer. It is hugely important to us that it carries the potential for better informed decision-making for women themselves and treatments designed around women's individual needs and choices."
This study is supported by researchers from Queen Mary University of London; Barts Health NHS Trust; University of Hertfordshire; University College London; Manchester University; Guy's Hospital, London; Nottingham University Hospitals NHS Trust; Ninewells Hospital, NHS Tayside; Addenbrooke's Hospital, Cambridge; London School of Hygiene and Tropical Medicine.

More information

Research paper: 'Attitudes towards risk?reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study'. F Gaba, O Blyuss, D Chandrasekaran, M Osman, S Goyal, C Gan, L Izatt, V Tripathi, I Esteban, L McNicol, K Ragupathy, R Crawford, DG Evans, R Legood, U Menon, R Manchanda. British Journal of Obstetrics and Gynaecology. Doi 10.1111/1471-0528.16424

Queen Mary University of London

Related Ovarian Cancer Articles from Brightsurf:

Ovarian cancer cells cooperate to metastasize
In a study on human ovarian cancer cells in mice, Harvard Medical School researchers discovered a transient, cooperative interaction between cell subpopulations that allows otherwise nonmetastatic tumor cells to become aggressive and spread.

Photodynamic therapy used to treat ovarian cancer
Photodynamic therapy (PDT) is one of the most promising methods of treating localized tumors.

Studying the development of ovarian cancer with organoids
Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous ovarian cancer in mini-versions, or organoids, of the female reproductive organs of the mouse.

New class of drugs could treat ovarian cancer
A team of researchers across the University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.

How to catch ovarian cancer earlier
Ovarian cancer is often diagnosed too late for effective treatment.

New compound could help treat ovarian cancer
Scientists from the University of Sheffield have discovered a compound that could be more effective in treating certain cancers than standard chemotherapy.

Epigenetic markers of ovarian cancer
Insilico Medicine and its collaborators from Johns Hopkins and Insilico Medicine, used an integrated approach by coupling identification of genome-wide expression patterns in multiple cohorts of primary ovarian cancer samples and normal ovarian surface epithelium with innovative computational analysis of gene expression data, leading to the discovery of novel cancer-specific epigenetically silenced genes.

Ovarian cancer statistics, 2018
A new report from the American Cancer Society provides an overview of ovarian cancer occurrence and mortality data.

Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.

TGen-led study finds potent anti-cancer drug effect in rare ovarian cancer
An anti-cancer drug used to fight leukemia shows promise against a rare and aggressive type of ovarian cancer -- small cell carcinoma of the ovary hypercalcemic type (SCCOHT) -- which strikes young women and girls, according to a study led by the TGen.

Read More: Ovarian Cancer News and Ovarian Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to